- Open Access
HIV-1 Vpr activates host CRL4-DCAF1 E3 ligase to degrade histone deacetylase SIRT7
Virology Journal volume 18, Article number: 48 (2021)
Vpr is a virion-associated protein that is encoded by lentiviruses and serves to counteract intrinsic immunity factors that restrict infection. HIV-1 Vpr mediates proteasome-dependent degradation of several DNA repair/modification proteins. Mechanistically, Vpr directly recruits cellular targets onto DCAF1, a substrate receptor of Cullin 4 RING E3 ubiquitin ligase (CRL4) for poly-ubiquitination. Further, Vpr can mediate poly-ubiquitination of DCAF1-interacting proteins by the CRL4. Because Vpr-mediated degradation of its known targets can not explain the primary cell-cycle arrest phenotype that Vpr expression induces, we surveyed the literature for DNA-repair-associated proteins that interact with the CRL4-DCAF1. One such protein is SIRT7, a deacetylase of histone 3 that belongs to the Sirtuin family and regulates a wide range of cellular processes. We wondered whether Vpr can mediate degradation of SIRT7 via the CRL4-DCAF1.
HEK293T cells were transfected with cocktails of plasmids expressing DCAF1, DDB1, SIRT7 and Vpr. Ectopic and endogeneous levels of SIRT7 were monitered by immunoblotting and protein–protein interactions were assessed by immunoprecipitation. For in vitro reconstitution assays, recombinant CRL4-DCAF1-Vpr complexes and SIRT7 were prepared and poly-ubiqutination of SIRT7 was monitored with immunoblotting.
We demonstrate SIRT7 polyubiquitination and degradation upon Vpr expression. Specifically, SIRT7 is shown to interact with the CRL4-DCAF1 complex, and expression of Vpr in HEK293T cells results in SIRT7 degradation, which is partially rescued by CRL inhibitor MNL4924 and proteasome inhibitor MG132. Further, in vitro reconstitution assays show that Vpr induces poly-ubiquitination of SIRT7 by the CRL4-DCAF1. Importantly, we find that Vpr from several different HIV-1 strains, but not HIV-2 strains, mediates SIRT7 poly-ubiquitination in the reconstitution assay and degradation in cells. Finally, we show that SIRT7 degradation by Vpr is independent of the known, distinctive phenotype of Vpr-induced cell cycle arrest at the G2 phase,
Targeting histone deacetylase SIRT7 for degradation is a conserved feature of HIV-1 Vpr. Altogether, our findings reveal that HIV-1 Vpr mediates down-regulation of SIRT7 by a mechanism that does not involve novel target recruitment to the CRL4-DCAF1 but instead involves regulation of the E3 ligase activity.
HIV-1 encodes several accessory proteins that counteract anti-viral intrinsic immunity [1, 2]. Among these accessory proteins, Vpr is enigmatic, and the precise mechanisms by which it antagonizes antiviral responses are not clearly understood. Currently, it is widely accepted that Vpr directly loads post-replication DNA repair proteins onto DCAF1, a substrate receptor subunit of Cullin 4 RING E3 ubiquitin ligase (CRL4), thereby mediating their proteasome-dependent degradation [3, 4]. Further, Vpr may also activate the CRL4 such that cellular factors interacting with DCAF1 during homeostasis are degraded upon HIV infection [5,6,7]. However, the breadth of biological phenotypes associated with Vpr are not fully explained by degradation of known cellular targets, suggesting that additional substrates of the Vpr-bound CRL4-DCAF1 remain to be identified.
Sirtuin 7 (SIRT7) is a member of the Sir2 protein family, possessing a NAD+-dependent protein deacetylase catalytic core domain [8, 9]. Localized in the nucleus, SIRT7 deacetylates several nuclear proteins including histone 3 at lysine 18, which facilitates recruitment of DNA repair proteins at damaged sites . Considering that SIRT7 was previously shown to inhibit proteasome-dependent degradation of nuclear receptor TR4 by direct interaction with the CRL4-DCAF1  and possesses activities to regulate transcription, DNA damage repair, and DNA replication [12,13,14], we explored the possibility that SIRT7 is a target of Vpr. In the present study, we establish a biochemical link between SIRT7 and CRL4-DCAF1-Vpr. Specifically, using in vitro reconstitution assays, we show poly-ubiquitination of SIRT7 by the Vpr-bound CRL4-DCAF1 and Vpr-mediated degradation of SIRT7 in a CRL4- and proteasome-dependent manner. Importantly, Vpr isolated from various HIV-1 strains and their ancestral virus, SIVcpz (Simian Immunodeficieny Virus infecting chimpanzee), but not from HIV-2, induces degradation of SIRT7, suggesting that Vpr-dependent degradation of SIRT7 has been conserved during zoonotic events.
Cloning and plasmid constructions
HIV-1 NL4-3 Vpr and its mutants, various Vpr clones from HIV-1 YU2, LAI, Q23, M, N and O group, SIVcpz PTT, and PTS were cloned into the pcDNA3.1 vector (Thermo Fisher Scientific) with an HA epitope tag at the N-terminus. HA-tagged SIRT7, FLAG and HA-tagged SIRT7, FLAG or HA-tagged DCAF1, and Myc and HA-tagged DDB1 were cloned into the pcDNA3.1 vector. For E.coli expression, SIRT7 with 6X His tag at the N-terminus was cloned into the pET28 (EMD Bioscience). All other clones were described previously [5, 15, 16].
In vitro ubiquitination assays
E1 (UBA1, 0.5 µM), E2 (Ubc-5Hb, 5 µM), and appropriate E3 ubiquitin ligase complexes (mixtures of CUL4A-RBX1 and DDB1-DCAF1, DDB1-DCAF1-Vpr or DDB1-DCAF1-Vpx at each 0.5 µM) were incubated with 1 µM of SIRT7 and 5 µM of ubiquitin in a buffer containing 10 mM Tris–HCl, pH 7.5, 150 mM NaCl, 5% glycerol, 20 units/mL pyrophosphatase, 1 mM TCEP, and 5 mM ATP. The reaction mixtures were terminated with SDS-PAGE sample loading buffer after 5 15, and 45 min. The degree of ubiquitination was detected by immunoblotting with the anti-SIRT7 antibody.
Mammalian cell lines, transfection, immunoprecipitation and western blotting
Human embryonic kidney cell lines (HEK293T from ATCC) were maintained in advanced DMEM, supplemented with Glutamine and 10% (v/v) fetal bovine serum. A day before transfection, approximately 3 × 106 cells were seeded on a 100 mm dish. Transfection was performed with a mixture of pcDNA plasmids expressing specific proteins, as indicated, using Lipofectamine 3000 (Thermo Fisher Scientific) with empty pcDNA vector plasmid as a balance. After 48 h, cells were harvested and lysed with sonication in the lysis buffer (50 mM Tris, 150 mM NaCl, 0.5% NP-40, pH 7.5) with complete protease inhibitor mixture (Sigma). Some cell lysate was mixed with loading buffer and heated at 95 °C for 5 min. For immunoprecipitation, the cleared cell lysate was incubated with 20 µL of anti-FLAG magnetic beads (Sigma) with shaking at 4 °C for 5 h. The beads were washed with the lysis buffer three times and bound proteins were eluted with FLAG peptides at 0.1 mg/mL. Samples were subjected to SDS-PAGE and Western Blotting analysis with appropriate antibodies. Antibodies used in the currernt study included anti-HA (COVANCE), anti-FLAG (Abnova), anti-DDB1 (Sigma), anti-Actin (Sigma), anti-DCAF1 (Santa Cruz), anti-SIRT7 (Santa Cruz), anti-Goat IgG (Santa Cruz), anti-Rabbit IgG (Sigma), and anti-Mouse IgG (Sigma).
Cell cycle assays
HEK293T cells seeded on 6-well plates were transfected with pcDNA plasmid expressing Vpr, Vpx or empty vector. Cells were collected 48 h after transfection. After fixation with 70% ethanol for 30 min and two washes with PBS, cells were resuspended in 0.5 ml 10 μg/ml propidium iodide staining solution. After staining for 30 min at room temperature, cell profiles were analyzed by flow cytometry (BD LSRII SORP). Cell cycle data were analyzed with FlowJo software (Tree Star Inc., Ashland, OR).
SIRT7 is a CRL4-DCAF1 binding protein
SIRT7 was previously reported to interact with the CRL4-DCAF1 and modulate its ubiquitin ligase activity [11, 17, 18]. Consistent with those findings, in co-immunoprecipitation experiments, we observed an interaction between DCAF1 and SIRT7, despite some non-specific interaction of SIRT7 and anti-FLAG antibody beads (Fig. 1a). Further, co-immunoprecipitation experiments against SIRT7 after co-expression of DDB1 or DDB1 and DCAF1 suggest that SIRT7 is a binding partner of the CRL4-DCAF1 (Fig. 1b).
We next wondered whether SIRT7 would still interact with the CRL4-DCAF1 in the presence of Vpr. Co-immunoprecipitation experiments showed that SIRT7 indeed forms a stable complex with DDB1, DCAF1 and Vpr (Fig. 1c). However, we did not see appreciable interaction between Vpr and SIRT7 (Fig. 1d). Together, these data suggest that both SIRT7 and Vpr form a stable complex with the CRL4-DCAF1.
SIRT7 is poly-ubiquitinated by the CRL4-DCAF1 in a Vpr-dependent manner for proteasome-dependent degradation
Vpr can mediate proteasome-dependent degradation of several cellular targets by two distinctive mechanisms: Vpr, associated with DCAF1, directly interacts and recruits cellular targets for poly-ubiquitination by the CRL4, or Vpr, by binding DCAF1, activates the E3 ligase activity and mediates poly-ubiquitination of DCAF1-interacting proteins (see Fig. 6 and Discussion). Since we found that both SIRT7 and Vpr simultaneously interact with DDB1 and DCAF1 (Fig. 1c), we asked whether Vpr modulates the ubiquitin ligase activity of CRL4-DCAF1 for poly-ubiquitination of SIRT7. To that end, we performed in vitro ubiquitination assays with reconstituted CRL4-DCAF1 and CRL4-DCAF1-Vpr complexes (Fig. 2a). Here, we used the C-terminal domain of DCAF1 (residues 1045–1396), which is sufficient for interacting with DDB1, Vpr and SIRT7. Poly-ubiquitination of SIRT7 was apparent only in the presence of Vpr (Compare lane 1–3 versus lanes 4–6 in Fig. 2a). Transient expression of SIRT7 and Vpr resulted in down-regulation of SIRT7 in a Vpr-dose dependent manner (Fig. 2b). Treatment of those cells with proteasome inhibitor, MG132 moderated Vpr-dependent down-regulation of SIRT7 (Fig. 2c). Further, the level of endogenous SIRT7 protein decreased with increasing ectopic expression of Vpr (Fig. 2d). Taken together, these data suggest that Vpr enhances the activity of CRL4-DCAF1 to poly-ubiquitinate SIRT7 for proteasome-dependent degradation.
To further understand the role of Vpr in mediating SIRT7 down-regulation, we generated a Vpr mutant R62D/F69A. These two residues of Vpr reside at the DCAF1 binding interface (Fig. 3a). We previously showed that single R62D or F69A mutation affected Vpr interaction with DCAF1, respectively, and F69A mutation reduced Vpr-mediated Exo1 association with DDB1 and DCAF1 [15, 27]. The Vpr mutant does not form a stable complex with DCAF1 (Fig. 3b) and cannot mediate down-regulation of SIRT7 (Fig. 3c). Further, treatment of cells ectopically expressing Vpr and SIRT7 with the CRL inhibitor, MLN4924 resulted in elevated SIRT7 level (Fig. 3d). Altogether, these data suggest that Vpr binding to DCAF1 is necessary to mediate SIRT7 degradation in a CRL4-dependent manner.
SIRT7 degradation is a conserved feature of HIV-1 Vpr and SIVcpz Vpr
The CRL4-DCAF1 is also usurped by an ortholog of HIV-1 Vpr, HIV-2/SIVmac (SIV isolated from macaque monkey) Vpx, which induces degradation of SAMHD1 and HUSH complex [19,20,21,22]. Structural studies suggested that both Vpr and Vpx essentially bind DCAF1 in the same manner, using a common interface, and recruit their respective cellular targets using unique interfaces [15, 23,24,25]. Thus, we asked whether Vpx can also induce degradation SIRT7 by activating the CRL4-DCAF1. Surprisingly, SIVmac Vpx, even at a higher level than Vpr, did not enhance degradation of SIRT7 (Fig. 4a). In vitro ubiquitination confirmed that Vpx does not significantly enhance the CRL4-DCAF1 activity to mediate poly-ubiquitination of SIRT7 (Fig. 4b). Thus, the data suggest that CRL4-DCAF1 activation is a unique function inherent only to HIV-1 Vpr.
All the above studies were performed with Vpr isolated from the HIV-1 NL4-3 strain. To explore whether Vpr-dependent SIRT7 degradation is evolutionarily conserved among various HIV-1 strains, we co-expressed SIRT7 with Vpr isolated from HIV-1 YU2, LAI, Q23, M, N or O group (Fig. 4c). Each tested Vpr protein reduced the SIRT7 level in a dose-dependent manner. Further, Vpr isolated from SIVcpz PTT and PTS strains, evolutionary predecessors of HIV-1, also reduced the level of SIRT7 (Fig. 4d). However, Vpr isolated from HIV-2 A1, A2 or B strain, that are closely related SIV isolated from sooty mangabeys, did not efficiently reduce SIRT7 level (Fig. 4e). In line with our observation, recent quantitative proteomics with CEM-T4 T cells transduced with VSVg-pseudotyped HIV containing HIV-1/SIVcpz Vpr, but not other SIV or HIV-2 Vpr, showed reduction in SIRT7 cellular level, . In vitro ubiquitination assays of SIRT7 were performed with CRL4-DCAF1 in complex with various Vpr proteins and confirmed that SIRT7 is targeted for poly-ubiquitination (Fig. 4f). On the other hand, Vpx isolated from SIVmac and Vpr isolated from HIV-2 A1 did not siginificantly enhance the ubiquitin ligase activity of CRL4-DCAF1 (Fig. 4g). Thus, taken altogether, the data suggest that SIRT7 degradation is a conserved function of Vpr in HIV-1 and SIVcpz.
SIRT7 degradation and G2 arrest are independent functions of HIV-1 Vpr
One distinctive phenotype that has been associated with HIV-1 Vpr expression in cycling cells is G2 arrest. HEK293T cells transfected with HIV-1 Vpr, but not with SIVmac Vpx, display accumulation in G2 (Fig. 5a, upper panels). Mechanistically, the C-terminus of Vpr has been proposed to recruit unidentified cell cycle related factor(s) onto the CRL4-DCAF1 for proteasome-dependent degradation, activating damaged DNA response pathways. Cell cycle analyses of HEK293T cells transfected with the Vpr mutant that is deficient for DCAF1-binding (R62D/F69A) or Vpr C-terminal mutants (residue 1–79, and R80A) confirmed this model (Fig. 5a, lower panels). Since SIRT7 participates in the damaged DNA response pathway, we tested whether the C-terminus of Vpr interacts with SIRT7 for its degradation (Fig. 5b). Both Vpr C-terminal mutants efficiently mediated SIRT7 degradation. Thus, Vpr-dependent SIRT7 degradation is independent of Vpr-induced G2 arrest.
The majority of phenotypic effects exerted by HIV-1 Vpr are closely associated with its interaction with the CRL4-DCAF1 complex. Mechanistically, Vpr possesses two protein–protein interfaces, one of which interacts with DCAF1 while the other directly binds cellular targets and recruits them for poly-ubiquitination by the CRL4-DCAF1 complex, resulting in proteasome-dependent degradation (Fig. 6a). For example, Uracil DNA glycosylase 2 (UNG2), Helicase-like transcription factor (HLTF) and Exonuclease I (EXO1) directly bind to Vpr, which binds to DCAF1 and thus bridging the target to the CRL4 [15, 16, 27]. In addition to this canonical mechanism of action, which is also utilized by other viral proteins to hijack CRLs to overcome anti-viral responses, Vpr induces degradation of native CRL4-DCAF1 interacting proteins (Fig. 6b), such as MUS81-EME, HDAC and TET2 [5,6,7]. In this study, we show that Vpr mediates degradation of another CRL4-DCAF1 interacting protein, SIRT7. We find that ectopic expression of HIV-1 Vpr reduces cellular SIRT7 level, which can be rescued by CRL E3 ligase inhibitor MNL4924 and proteasome inhibitor MG132. In vitro reconstitution assays show that Vpr induces poly-ubiquitination of SIRT7 by the CRL4-DCAF1. Vpr proteins isolated from different HIV-1 lineages or from ancestral SIVs that infect chimpanzee, but not from HIV-2, show an ability to degrade SIRT7 in the same manner, suggesting that SIRT7 down-regulation is beneficial to HIV-1 infection.
Several studies have suggested a functional link between histone acetylation state and HIV-1 replication. Proviral cDNA, which is reverse transcribed from viral RNA upon entry into the cell, is integrated into the host genome; active transcription from the integrated genome has been correlated with post-translational modification of histones such as hyper-acetylation [28, 29]. Further, treatment of HIV-1 latently infected cells with histone deacetylase (HDAC) inhibitors results in the transcriptional activation of the HIV-1 promoter and an increase in HIV-1 replication . Interestingly, HIV-1 Vpr targets class I HDACs on chromatin for proteasome-dependent degradation, by usurping the CRL4-DCAF1, and induces reactivation of latent HIV-1 provirus [6, 31]. In another pathway, Vpr-bound CRL4-DCAF1 degrades TET2 thereby inhibiting HDAC recruitment to the promoter of pro-inflammatory cytokine interleukin-6 (IL-6), whose expression enhances HIV-1 replication [7, 32]. Given that SIRT7 mediates transcriptional repression via histone 3 Lys18 acetylation , it is tempting to speculate that SIRT7 down-regulation by Vpr facilitates efficient HIV-1 replication. This possibility will be addressed in future studies.
Previous studies suggested that HIV-1 Vpr antagonizes several post-replication DNA repair machineries by usurping the CRL4-DCAF1. Importantly, recent reports showed that removal of HLTF and EXO1 is beneficial to HIV-1 replication [27, 34]. The observation that removal of these proteins only partially accounts for the phenotypic effect of Vpr implicates the existence of additional Vpr-counteracted machineries that restrict viral replication. Interestingly, Vpr recruits CRL4-DCAF1 to nuclear foci, where multiple DNA repair proteins, including SIRT7, are localized [10, 35]. The C-terminus of Vpr is essential for localization to nuclear foci as well as for induction of G2 cell cycle arrest, implying that degradation of nuclear foci bound cellular proteins induces DNA damage, leading to activation of the DNA damage response pathway and G2 arrest . Since Vpr-mediated degradation of HLTF, EXO1 and SIRT7 is independent of Vpr-induced G2 cell cycle arrest, searches for additional Vpr targets are needed.
HIV-1 Vpr mainly exerts its biological functions by interacting with the CRL4-DCAF1, thereby inducing proteasomal degradation of multiple host factors. We provide biochemical evidence that SIRT7 is another celluar target of Vpr from HIV-1 lienage.
Availability of data and materials
All data generated or anlalyzed during this study are included in the published article and all materials are available from the corresponding author on reasonable request.
Cullin 4 RING E3 ubiquitin ligase
DNA damage repair
Human immunodeficiency virus 1
Human immunodeficiency virus 2
Helicase-like transcription factor
Simian immunodeficiency virus
Viral protein R
Uracil DNA glycosylase 2
Collins DR, Collins KL. HIV-1 accessory proteins adapt cellular adaptors to facilitate immune evasion. PLoS Pathg. 2014;10:e1003851.
Malim MH, Emerman M. HIV-1 accessory proteins–ensuring viral survival in a hostile environment. Cell host microbe. 2008;3:388–98.
Romani B, Cohen EA. Lentivirus Vpr and Vpx accessory proteins usurp the cullin4-DDB1 (DCAF1) E3 ubiquitin ligase. Curr opin Virol. 2012;2:755–63.
Fabryova H, Strebel K (2019) Vpr and its cellular interaction partners: R we there yet? Cells 8
Zhou X, DeLucia M, Ahn J. SLX4-SLX1 protein-independent down-regulation of MUS81-EME1 protein by HIV-1 viral protein R (Vpr). J Biol Chem. 2016;291:16936–47.
Romani B, Baygloo NS, Hamidi-Fard M, Aghasadeghi MR, Allahbakhshi E. HIV-1 Vpr protein induces proteasomal degradation of chromatin-associated class I HDACs to overcome latent infection of macrophages. J Biol Chem. 2016;291:2696–711.
Lv L, Wang Q, Xu Y, Tsao LC, Nakagawa T, Guo H, Su L, Xiong Y. Vpr targets TET2 for degradation by CRL4(VprBP) E3 ligase to sustain IL-6 expression and enhance HIV-1 replication. Mol Cell. 2018;70(961–970):e965.
Blank MF, Grummt I. The seven faces of SIRT7. Transcription. 2017;8:67–74.
Vazquez BN, Thackray JK, Serrano L. Sirtuins and DNA damage repair: SIRT7 comes to play. Nucleus. 2017;8:107–15.
Vazquez BN, Thackray JK, Simonet NG, Kane-Goldsmith N, Martinez-Redondo P, Nguyen T, Bunting S, Vaquero A, Tischfield JA, Serrano L. SIRT7 promotes genome integrity and modulates non-homologous end joining DNA repair. EMBO J. 2016;35:1488–503.
Yoshizawa T, Karim MF, Sato Y, Senokuchi T, Miyata K, Fukuda T, Go C, Tasaki M, Uchimura K, Kadomatsu T, Tian Z, Smolka C, Sawa T, Takeya M, Tomizawa K, Ando Y, Araki E, Akaike T, Braun T, Oike Y, Bober E, Yamagata K. SIRT7 controls hepatic lipid metabolism by regulating the ubiquitin-proteasome pathway. Cell Metab. 2014;19:712–21.
Martinez-Redondo P, Santos-Barriopedro I, Vaquero A. A big step for SIRT7, one giant leap for Sirtuins... in cancer. Cancer Cell. 2012;21:719–21.
Paredes S, Villanova L, Chua KF. Molecular pathways: emerging roles of mammalian Sirtuin SIRT7 in cancer. Clin cancer res. 2014;20:1741–6.
Paredes S, Chua KF. SIRT7 clears the way for DNA repair. EMBO J. 2016;35:1483–5.
Wu Y, Zhou X, Barnes CO, DeLucia M, Cohen AE, Gronenborn AM, Ahn J, Calero G. The DDB1-DCAF1-Vpr-UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction. Nat Struct Mol Biol. 2016;23:933–40.
Zhou X, DeLucia M, Hao C, Hrecka K, Monnie C, Skowronski J, Ahn J. HIV-1 Vpr protein directly loads helicase-like transcription factor (HLTF) onto the CRL4-DCAF1 E3 ubiquitin ligase. J Biol Chem. 2017;292:21117–27.
Mo Y, Lin R, Liu P, Tan M, Xiong Y, Guan KL, Yuan HX. SIRT7 deacetylates DDB1 and suppresses the activity of the CRL4 E3 ligase complexes. FEBS J. 2017;284:3619–36.
Karim MF, Yoshizawa T, Sobuz SU, Sato Y, Yamagata K. Sirtuin 7-dependent deacetylation of DDB1 regulates the expression of nuclear receptor TR4. Biochem Biophys Res Comm. 2017;490:423–8.
Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474:658–61.
Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474:654–7.
Chougui G, Munir-Matloob S, Matkovic R, Martin MM, Morel M, Lahouassa H, Leduc M, Ramirez BC, Etienne L, Margottin-Goguet F. HIV-2/SIV viral protein X counteracts HUSH repressor complex. Nat Microbiol. 2018;3:891–7.
Yurkovetskiy L, Guney MH, Kim K, Goh SL, McCauley S, Dauphin A, Diehl WE, Luban J. Primate immunodeficiency virus proteins Vpx and Vpr counteract transcriptional repression of proviruses by the HUSH complex. Nat Microbiol. 2018;3:1354–61.
Schwefel D, Groom HC, Boucherit VC, Christodoulou E, Walker PA, Stoye JP, Bishop KN, Taylor IA. Structural basis of lentiviral subversion of a cellular protein degradation pathway. Nature. 2014;505:234–8.
Schwefel D, Boucherit VC, Christodoulou E, Walker PA, Stoye JP, Bishop KN, Taylor IA. Molecular determinants for recognition of divergent SAMHD1 proteins by the lentiviral accessory protein Vpx. Cell Host Microbe. 2015;17:489–99.
Wu Y, Koharudin LM, Mehrens J, DeLucia M, Byeon CH, Byeon IJ, Calero G, Ahn J, Gronenborn AM. Structural basis of clade-specific engagement of SAMHD1 (sterile alpha motif and histidine/aspartate-containing protein 1) restriction factors by lentiviral viral protein X (Vpx) virulence factors. J Biol Chem. 2015;290:17935–45.
Greenwood EJD, Williamson JC, Sienkiewicz A, Naamati A, Matheson NJ, Lehner PJ. Promiscuous targeting of cellular proteins by Vpr drives systems-level proteomic remodeling in HIV-1 infection. Cell Rep. 2019;27(1579–1596):e1577.
Yan J, Shun MC, Hao C, Zhang Y, Qian J, Hrecka K, DeLucia M, Monnie C, Ahn J, Skowronski J. HIV-1 Vpr reprograms CLR4(DCAF1) E3 ubiquitin ligase to antagonize exonuclease 1-mediated restriction of HIV-1 infection. mBio. 2018;9:e01732-e1818.
Ruelas DS, Greene WC. An integrated overview of HIV-1 latency. Cell. 2013;155:519–29.
Romani B, Allahbakhshi E. Underlying mechanisms of HIV-1 latency. Virus Genes. 2017;53:329–39.
Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO Jl. 1996;15:1112–20.
Romani B, Kamali Jamil R, Hamidi-Fard M, Rahimi P, Momen SB, Aghasadeghi MR, Allahbakhshi E. HIV-1 Vpr reactivates latent HIV-1 provirus by inducing depletion of class I HDACs on chromatin. Sci rep. 2016;6:31924.
Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, Zhao D, Liu Y, Wang C, Zhang X, Su X, Liu J, Ge W, Levine RL, Li N, Cao X. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525:389–93.
Barber MF, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M, Moqtaderi Z, Tennen RI, Paredes S, Young NL, Chen K, Struhl K, Garcia BA, Gozani O, Li W, Chua KF. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012;487:114–8.
Yan J, Shun MC, Zhang Y, Hao C, Skowronski J. HIV-1 Vpr counteracts HLTF-mediated restriction of HIV-1 infection in T cells. Proc Natl Acad Sci USA. 2019;116:9568–77.
Belzile JP, Abrahamyan LG, Gerard FC, Rougeau N, Cohen EA. Formation of mobile chromatin-associated nuclear foci containing HIV-1 Vpr and VPRBP is critical for the induction of G2 cell cycle arrest. PLoS Pathog. 2010;6:e1001080.
We thank Teresa Brosenitsch for critical reading of the manuscript and editorial help. We thank University of Pittsburgh Unified Flow Core training specialist Aarika MacIntyre for assistance with the cell cycle assay experiments.
This work was supported, in whole or in part, by the National Institute of Health Grants P50AI150481 (JA), R01AI150458 (JA).
Ethics approval and consent to participate
Conset for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zhou, X., Monnie, C., DeLucia, M. et al. HIV-1 Vpr activates host CRL4-DCAF1 E3 ligase to degrade histone deacetylase SIRT7. Virol J 18, 48 (2021). https://doi.org/10.1186/s12985-021-01514-2
- Ubiquitin ligase
- Protein degradation
- Histone deacetylase